Rates of positive lung cancer screening examinations in academic versus community practice.

Health facilities lung mass screening radiology

Journal

Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875

Informations de publication

Date de publication:
Aug 2020
Historique:
entrez: 21 9 2020
pubmed: 22 9 2020
medline: 22 9 2020
Statut: ppublish

Résumé

The benefits and harms of lung cancer screening reported in the National Lung Screening Trial (NLST) likely differ from those observed in academic and community settings. High rates of positive screening findings in the NLST led to the development of the Lung CT Screening Reporting and Data System (Lung-RADS) to standardize interpretation and reporting. We conducted a prospective observational study of lung cancer screening data from four lung cancer screening sites in North Carolina to compare prospective use of Lung-RADS in a real-world screened population versus Lung-RADS retrospectively applied to the NLST, and to determine if Lung-RADS assessment use differs in academic versus community settings. We included 4,037 screening examinations from 11/2014 to 12/2018 in academic and community sites and 75,126 NLST LDCT screening exams. On baseline screening exams, the proportion of positive LDCT exams was higher in community versus academic sites or the NLST (17.7%

Identifiants

pubmed: 32953524
doi: 10.21037/tlcr-19-673
pii: tlcr-09-04-1528
pmc: PMC7481616
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1528-1532

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016086
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA212014
Pays : United States

Informations de copyright

2020 Translational Lung Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-19-673). LMH, TB and RHV report grants from NIH/NCI during the conduct of the study. MPR reports grants from NIH/NCI during the conduct of the study; Consultant for a Research Workshop held by Johnson & Johnson; Chair, Medical and Scientific Advisory Board for bioAffinity Technologies; and Member, Medical and Scientific Advisory Board for Biodesix. LB has no conflicts of interest to declare.

Références

N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Ann Am Thorac Soc. 2017 Dec;14(12):1827-1835
pubmed: 28683215
Ann Intern Med. 2015 Apr 7;162(7):485-91
pubmed: 25664444
Radiology. 2011 Jan;258(1):243-53
pubmed: 21045183
JAMA Oncol. 2018 Sep 1;4(9):1291-1293
pubmed: 30073301
Radiology. 2009 Dec;253(3):632-40
pubmed: 19789234
J Am Coll Radiol. 2019 Apr;16(4 Pt A):419-426
pubmed: 30146484
Ann Intern Med. 2014 Mar 4;160(5):330-8
pubmed: 24378917
Radiology. 2011 Dec;261(3):762-70
pubmed: 22031709
Cancer. 2015 Dec 15;121(24):4341-7
pubmed: 26372542
J Natl Cancer Inst. 2019 Apr 1;111(4):342-349
pubmed: 30698792

Auteurs

Louise M Henderson (LM)

Department of Radiology, The University of North Carolina, Chapel Hill, NC, USA.
Department of Epidemiology, The University of North Carolina, Chapel Hill, NC, USA.
The University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.

Leon Bacchus (L)

Department of Radiology, The University of North Carolina, Chapel Hill, NC, USA.

Thad Benefield (T)

Department of Radiology, The University of North Carolina, Chapel Hill, NC, USA.

Roger Huamani Velasquez (R)

Department of Radiology, The University of North Carolina, Chapel Hill, NC, USA.

M Patricia Rivera (MP)

The University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina, Chapel Hill, NC, USA.

Classifications MeSH